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Primary aldosteronism (PA) is a form of endocrine hyperten-sion caused by the overproduction of aldosterone from one or 
both adrenal glands mainly because of a unilateral aldosterone-
producing adenoma (APA) or bilateral adrenal hyperplasia.1 
Specific treatment by unilateral laparoscopic adrenalectomy 
(unilateral PA) or medical therapy with mineralocorticoid antag-
onists (bilateral PA) reverses the increased risk of stroke and heart 
disease in patients with PA compared with patients with essential 
hypertension.2–4 Adrenal venous sampling or adrenal computed 
tomographic scanning is used to differentiate unilateral from 
bilateral PA although alternative approaches are currently being 
investigated, including functional imaging using positron emis-
sion tomography/computed tomographic scanning with a radio-
labeled tracer and peripheral venous steroid profiling.5–10
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Immunohistochemistry using polyclonal11 or monoclonal 
antibodies12–14 to key enzymes involved in adrenal steroido-
genesis (CYP11B2, CYP11B1, and CYP17A1) has aided 
identification of pathological features contributing to aldoste-
rone overproduction.15–17 The histopathologic abnormalities 
present in unilateral PA are highly heterogeneous and include 
solitary functional unilateral adenoma, adenoma with adja-
cent hyperplasia of the zona glomerulosa, or unilateral diffuse 
hyperplasia with functional micronodules or hyperplasia with 
macronodules.17–21 Nests of CYP11B2-positive cells (aldoste-
rone-producing cell clusters [APCCs]) have been identified 
beneath the adrenal capsule and are present in normal adrenals 
and in the adrenal cortex adjacent to an APA.11,16,19,22,23 The 
occurrence of APCCs increases with age, and they frequently 
have somatic CACNA1D, ATP1A1, and ATP2B3 mutations 
that drive dysregulated aldosterone production in APAs and 
have been proposed as a likely source of constitutive aldoste-
rone production and possible precursors to APAs.6,22,24
Unlike unilateral PA, the pathophysiology of bilateral PA 
remains poorly understood, hampered, in part, by the scarce 
availability of resected adrenal specimens because of the 
medical, rather than surgical, management of bilateral PA. 
The PASO study (Primary Aldosteronism Surgical Outcome) 
established criteria to assess outcomes (complete, partial, or 
absent clinical and biochemical success) of patients after adre-
nalectomy for unilateral PA.25 Clinical outcomes were defined 
by blood pressure measurements and antihypertensive medi-
cation dosage, biochemical outcomes by plasma potassium, 
aldosterone, and renin measurements.25 Biochemical outcomes 
provide a quality measure of patient diagnosis with complete 
biochemical success defining the correct diagnosis and appro-
priate treatment, whereas absent and partial biochemical suc-
cess indicate persistent aldosteronism after surgery. Absent 
and partial biochemical success combined comprises around 1 
in every 20 patients with aldosterone lateralization performed 
by adrenal venous sampling, which presumably results from 
bilateral asymmetrical aldosterone overproduction.25
We hypothesised that patients with an absent or partial 
biochemical outcome comprise mainly cases of bilateral PA 
misdiagnosed as unilateral preoperatively. In a large multi-
center study with outcomes assessed in accordance with an 
international consensus, we analyzed the histopathology 
of 95 adrenals from patients operated for unilateral PA (43 
from patients with absent and partial biochemical success 
matched with 52 cases of complete biochemical success) and 
determined peripheral venous steroid profiles in a subgroup 
of these patients compared with patients diagnosed with 
bilateral PA.
Methods
The data that support the findings of this study are available from the 
corresponding author on reasonable request.
Patient Selection
The study included surgically resected adrenals of 95 patients col-
lected from 9 international centers that were diagnosed with unilat-
eral PA and classified with absent, partial, or complete biochemical 
success at 6 to 12 months after unilateral adrenalectomy in accor-
dance with the PASO consensus (Table S1 in the online-only Data 
Supplement).25 Patients with absent and partial biochemical success 
were matched for age (±5 years) and sex with patients with complete 
biochemical success from the same center. Peripheral venous plasma 
samples from patients of the Munich cohort (n=70) were analyzed 
by steroid profiling (absent or partial biochemical success, n=15; 
age and sex matched with complete success, n=28; and bilateral 
PA, n=27). All patients were diagnosed according to the Endocrine 
Society Guideline or the Japan Endocrine Society Guideline.1,26
Baseline and follow-up parameters of patients providing resected 
adrenals are shown in Table S2. Baseline parameters at study entry 
of patients providing peripheral plasma samples are shown in Table 
S3. Blood pressure measurements were recorded as described pre-
viously.25 Study approval was obtained from the appropriate institu-
tional review committees, and all patients gave informed consent in 
accordance with local ethical guidelines.
Histopathology
Successive paraffin-embedded adrenal tissue sections (4-µm thick) 
were immunostained for CYP11B2 (clone 41-17B), CYP11B1 (clone 
80-7-5), and CYP17A1 (clone 10-19-G6) developed by C.E.G-S.12,13 
All hematoxylin and eosin–stained sections and immunostained sec-
tions were independently assessed by a specialist in adrenal histo-
pathology (C.E.G-S.) and an experienced pathologist (I.C.). Both 
investigators were blinded for the surgical outcome of enrolled 
patients, and agreement was reached in cases of discordant scoring. 
The samples were scored for solitary functional adenoma (a single 
well-defined adenoma with positive CYP11B2 staining), hyperpla-
sia (multiple CYP11B2-positive macronodules, focal thickening of 
the zona glomerulosa with CYP11B2-positive immunostaining or 
CYP11B2-positive diffuse hyperplasia with or without CYP11B2-
positive micronodules), and APCCs (clusters of zona glomerulosa 
cells, CYP11B2 positive and CYP11B1 and CYP17A1 negative, 
localized in the subcapsular region extending into the zona fascicu-
lata).17,23 There were no significant differences in sex distribution or 
the average age of patients with a solitary functional adenoma, hyper-
plasia, or APCCs (Table S4).
Steroid Profiling Using Liquid Chromatography–
Tandem Mass Spectrometry
Blood was drawn by venipuncture at time of diagnosis of PA between 
8:00 and 10:00 am in a fasting state and processed according to stan-
dard operational procedures. The measurement of 15 adrenal ste-
roids using liquid chromatography–tandem mass spectrometry was 
performed in plasma of 15 patients with absent or partial biochemi-
cal success, 28 patients with complete biochemical success, and 27 
patients with a diagnosis of bilateral PA as described.9,10
Statistical Analysis
Statistical analyses were performed using SPSS, version 24. Data 
are shown as mean±SD, as medians and interquartiles, or as absolute 
numbers and percentages. Quantitative normally distributed variables 
were analyzed using 1-way ANOVA with a post hoc Bonferroni or a 
t test, group differences by Kruskal-Wallis or Mann-Whitney U tests 
for quantitative non-normally distributed variables, and χ2 or Fisher 
exact tests for categorical variables. A P value of <0.05 was consid-
ered significant. Linear discriminant analyses were performed in R, 
and decision tree analyses used MATLAB R2017b.
Results
Patient Characteristics
Patients with postsurgical complete biochemical success 
(n=52) had lower serum potassium concentrations at base-
line relative to patients with an absent+partial biochemical 
outcome (P=0.035; Table S2). No significant differences 
were detected in nodule size (at pathology or imaging) and 
in the appearance of the contralateral adrenal at imaging 
with respect to biochemical outcome. However, patients 
with absent+partial success displayed a lower lateralization 
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index and a higher contralateral ratio compared with patients 
with a complete biochemical outcome (Figure 1; Table S5). 
Genotype data were available for 46 of the 95 specimens; the 
proportion of adrenals with a KCNJ5 mutation was not signifi-
cantly higher in the complete biochemical outcome group (18 
adrenals carrying a KCNJ5 mutation of 30 [58%] genotyped 
samples compared with 7 of 16 [37%] in the absent group; 
P=0.292; Table S5).
Adrenal Histopathology of Resected Sample 
Specimens According to Biochemical Outcome
The distribution of solitary functional adenoma, hyperplasia, 
or APCCs in the complete, partial, and absent biochemical 
success groups is shown in Figure 2A. In the total sample 
set, the majority of adrenals showed a solitary functional 
adenoma (60 of 95 samples, 63%) with 50% (30 of 60) dis-
playing concurrent APCC in the adjacent cortex, 15% (9 of 
60) associated with cortical hyperplasia, and 48% (29 of 60) 
without hyperplasia or APCC (normal-appearing adjacent 
cortex). The complete biochemical outcome group displayed 
a significantly higher prevalence of solitary functional ade-
nomas compared with the absent+partial group (79% versus 
44%; P<0.001; Table). The immunohistopathology of the 
adjacent cortex surrounding a functional solitary adenoma 
was not perceivably different in patients with complete bio-
chemical success compared with an absent+partial biochemi-
cal outcome (Table).
Adrenals without a functional adenoma (without 
CYP11B2-positive immunostaining) comprised 37% of the 
total sample set (35 of 95 samples) with a higher prevalence 
noted in the absent+partial compared with the complete bio-
chemical success group (56% [24 of 43] versus 21% [11 of 
52]; P<0.001).
These adrenals showed a combination of mainly APCC and 
cortical hyperplasia, but nonfunctional adenomas (CYP11B2 
negative), without a concurrent functional adenoma, were 
present in 9 adrenals with 7 in the absent+partial group and 2 
in the complete biochemical success group (Table).
Adrenals from the absent+partial group had a higher prev-
alence of cortical hyperplasia (49% versus 21%; P=0.004), 
but no differences were observed in the proportion of adre-
nals with APCC or the average number of APCC per tissue 
section compared with the complete biochemical success 
group (Table).
Liquid Chromatography–Tandem Mass 
Spectrometry Peripheral Venous Steroid Profiling
There were no significant differences in concentrations of 
peripheral venous adrenal steroids according to histopatho-
logic feature (Table S6). Linear discriminant analyses of 
adrenal steroids correctly classified the presence or absence 
of solitary functional adenoma, hyperplasia, or APCC in 
84% to 88% of samples (misclassification rate, 0.12–0.16; 
Figure 3B), and decision tree analysis using steroids selected 
from estimate prediction certainties improved the accuracy of 
prediction to 91% to 93% (misclassification rate, 0.07–0.09; 
Figure 3C through 3F).
For the absent+partial group, concentrations of aldoste-
rone were higher in peripheral venous plasma compared with 
the bilateral PA group (P<0.001), and cortisone and 11-deoxy-
cortisol concentrations were significantly higher than in the 
complete group (P=0.021 and P=0.017, respectively; Table 
S7). Discriminant analysis correctly predicted biochemical 
outcome after adrenalectomy and diagnosis of bilateral PA 
in 53 of 70 patients (76%; Figure 4A). Decision tree anal-
ysis improved the correct classification to 60 of 70 cases 
(86%; misclassification rate, 0.14): all 15 patients with an 
absent+partial biochemical outcome after surgery were cor-
rectly predicted albeit 5 patients with complete biochemical 
success were incorrectly classified with an absent or partial 
biochemical outcome (Figure 4C). Linear discriminant anal-
ysis and decision trees of steroid measurements resulted in 
a higher accuracy for the classification of biochemical out-
comes compared with predictive models using adrenal venous 
sampling parameters (lateralization index and contralateral 
ratio; Table S8).
Discussion
We report the histopathology and peripheral venous steroid 
profiles associated with biochemical outcome after adrenal-
ectomy for unilateral PA. In a multicenter international study 
with differentiation of unilateral from bilateral PA by adrenal 
venous sampling, adrenalectomy for unilateral PA resulted in 
biochemical cure (complete biochemical success) in 94% of 
Figure 1. Adrenal venous sampling (AVS) 
results stratified for biochemical outcomes. Box 
and whisker plots showing AVS results stratified 
for biochemical outcomes. Patients with absent 
or partial biochemical success compared with 
complete success after adrenalectomy have 
lower lateralization indices (A) and higher 
contralateral ratios (B). Horizontal lines within 
boxes indicate the median, and box and 
whiskers represent the 25th to 75th and 5th to 
95th percentiles, respectively. n indicates the 
number of patients in each group, and a Mann-
Whitney U test was used to calculate P values.
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patients thereby indicating the correct diagnosis and appro-
priate treatment.25,27,28 Partial or absent biochemical success 
classifies patients with bilateral aldosterone excess who were 
presumably misdiagnosed as unilateral (instead of bilateral) 
preoperatively.25 In the present study, the lower lateraliza-
tion index and the higher contralateral ratio of patients with 
absent+partial biochemical outcomes would be consistent 
with the higher aldosterone production from the contralateral 
adrenal compared with the complete biochemical success 
group, despite a similar incidence of abnormalities detected 
by adrenal imaging.
The development of specific antibodies to CYP11B2 and 
CYP11B1 has revealed the complex heterogeneity of adre-
nal histopathology in PA.11,12,17 Immunostaining of CYP11B2 
identifies cells comprising the likely origin of constitutive 
aldosterone production and classifies diverse histopathologic 
subtypes of PA.15–17 Unilateral aldosterone excess is usually 
produced from an APA29 frequently accompanied by APCCs 
in the hyperplastic adjacent cortical tissue.15,19
In a multicenter study of patients diagnosed with uni-
lateral PA, Åkerström et al21 reported adenomas without 
associated hyperplasia in 287 of 348 (82%), adenomas with 
associated hyperplasia in 52 of 348 (15%), and hyperpla-
sia with macronodules or micronodules in 9 of 348 (3%) of 
sample specimens. A higher prevalence of cortical hyperplasia 
has been reported by others30,31 with multinodular hyperplasia 
or diffuse hyperplasia present in 54 and 12 resected adrenals, 
respectively, from 122 patients with postsurgical biochemi-
cal cure.31 No association of histopathology with persistent 
PA was found in 6 patients with persistent PA and recurrent 
PA reported in 3 of 79 patients with long-term follow-up data 
who were previously biochemically cured.31 Few studies have 
addressed the histopathology of bilateral PA. A study on 25 
resected adrenals from patients with undetectable abnormali-
ties by computed tomography scanning included 13 adrenals 
from patients with bilateral PA that displayed an increased 
Figure 2. Heterogeneous histopathology of resected adrenals from patients with primary aldosteronism. The diverse histopathology of resected adrenals 
in this cohort is shown with hematoxylin and eosin (H&E) staining and CYP11B2 immunostaining as indicated. A–C, Adrenals without a functional adenoma 
showing the various histopathology of this subgroup. aldosterone-producing cell cluster (APCC) is indicated with a single arrow and hyperplasia with a double 
arrow (scale bar=2 mm). These 3 adrenals were from patients with postsurgical absent or partial biochemical success. D and E, Examples of histopathologic 
features classified in this study: solitary functional adenoma (D), hyperplasia of the zona glomerulosa (E), and an APCC (F; scale bars=200 µm).
Table. Histopathology of Adrenals From Patients Stratified by Biochemical 
Outcome After Adrenalectomy
Variable
Total Cohort, 
n (%)
Biochemical Outcome
P ValueA+P C
Total 95 (100%) 43 (45%) 52 (55%)  
Solitary functional 
adenoma
60 (63%) 19 (44%) 41 (79%) <0.001
  Normal-appearing 
adjacent cortex
29 (48%) 9 (47%) 20 (49%) 0.919
  Hyperplasia 9 (15%) 5 (26%) 4 (10%) 0.200
  APCC 30 (50%) 10 (53%) 20 (49%) 0.781
No functional adenoma 35 (37%) 24 (56%) 11 (21%) <0.001
  CYP11B2-negative 
adenoma
9 (26%) 7 (29%) 2 (18%) 0.403
  Hyperplasia 23 (66%) 16 (67%) 7 (64%) 0.576
  APCC 27 (77%) 18 (75%) 9 (81%) 0.508
Hyperplasia 32 (34%) 21 (49%) 11 (21%) 0.004
APCC 57 (60%) 28 (65%) 29 (56%) 0.355
APCC number (sample 
section)
3.2±2.9 3.2±3.1 3.3±2.8 0.641
Values indicate absolute numbers with proportions in parenthesis (%) 
or average numbers±SD. P values were calculated using χ2 or Fisher exact 
tests or Mann-Whitney U tests as appropriate. A indicates absent biochemical 
success after surgery; APCC, aldosterone-producing cell cluster; C, complete 
biochemical success after surgery; CYP11B2, aldosterone synthase; and P, 
partial biochemical success after surgery.
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incidence of diffuse functional hyperplasia compared with 
adrenals from unilateral PA.16
In a large sample set of 43 resected adrenals from patients 
with absent+partial biochemical success after adrenalectomy 
for unilateral PA, we show an increased prevalence of cortical 
hyperplasia in adrenals in agreement with the proposal that 
nodular hyperplasia may comprise a risk factor for persistent 
aldosteronism after surgery.32 We also show the increased 
incidence of solitary functional adenomas (APAs) in the com-
plete biochemical success group. Functional adenomas were 
Figure 3. Classification of adrenal histopathology in primary aldosteronism according to peripheral venous steroid concentrations. The distribution of 
histopathologic features (1, solitary functional adenoma; 2, hyperplasia; and 3, aldosterone-producing cell cluster [APCC]) stratified for biochemical outcome 
(indicated by an arrow) is represented in (A). Linear discriminant analyses using peripheral venous steroid concentrations was used to generate receiver 
operating characteristic curves with areas under the curves (inset) and tables showing the real and estimated presence (yes) or absence (no) of solitary 
functional (SF) adenomas, hyperplasia, and APCCs (B). The steroids used in each model are shown in Table S9 with linear discriminant coefficients and 
cutoffs for prediction of the presence of SF adenoma, hyperplasia, or APCC. Decision tree analyses improved the prediction of histopathology by steroid 
measurements: decision trees with numbers indicating steroid concentrations in ng/mL predicting the presence (yes) or absence (no) of a solitary functional 
(SF) adenoma (C); hyperplasia (D) and APCCs (E) are shown with an accompanying table with the real and estimated presence (yes) and absence (no) 
of each histopathologic feature. Steroids used for decision tree analysis were selected from their estimated predictive performance (F). DHEA indicates 
dehydroepiandrosterone; and DHEAS, dehydroepiandrosterone sulfate.
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often associated with APCCs in the adjacent cortex, more 
frequently than with hyperplasia. There were no perceivable 
differences in the prevalence or numbers of APCC per sample 
section between biochemical outcomes although the potential 
association of somatic mutations in APCCs with biochemical 
outcomes cannot be excluded.
Liquid chromatography–tandem mass spectrometry mea-
surements of plasma adrenal steroids predicted the presence 
or absence of a solitary functional adenoma, hyperplasia, or 
APCCs. The association of histopathology in PA with adre-
nal steroid concentrations ostensibly underlies or contributes 
to the classification of postsurgical biochemical outcomes 
Figure 4. Classification of biochemical outcomes after adrenalectomy and diagnosis of bilateral adrenal hyperplasia (BAH) according to peripheral venous 
steroid concentrations. Discriminant analysis with 9 steroids (androstenedione, cortisol, cortisone, 11-deoxycortisol, dehydroepiandrosterone (DHEA), 
DHEA sulfate (DHEAS), pregnenolone, 18-hydroxycortisol, and 18-oxocortisol) generated receiver operating characteristic curves with areas under the 
curves (inset) and a table showing real and estimated biochemical outcomes (absent+partial and complete biochemical success) and diagnosis of bilateral 
primary aldosteronism (PA; BAH) (A). The steroids used in each model are shown in Table S9 with linear discriminant coefficients and cutoffs for prediction of 
absent+partial biochemical success. Decision tree analysis using steroids based on estimated predictive performance (B) improved the correct classification 
of biochemical outcomes and diagnosis of bilateral PA. Numbers in the decision tree indicate steroid concentrations in ng/mL (C).
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by steroid profiling, which herein identified all patients with 
absent+partial biochemical success from patients with bio-
chemical cure or from nonoperated patients.
Strengths and Limitations of the Study
The strengths of the study are the large multicenter sample 
cohort comprising the largest reported sample set of resected 
adrenals from patients with postsurgical absent+partial bio-
chemical success that were matched with a control group 
(complete biochemical success) and the strict standard-
ized PASO criteria used to assess biochemical outcomes. A 
limitation is the small size of the study population used for 
steroid profiling, in particular, the number of patients with 
absent+partial biochemical success. Nonetheless, in the 
Munich cohort, adrenal steroid concentrations in peripheral 
plasma correctly predicted postsurgical absent+partial bio-
chemical success in all 15 patients—an association possibly 
driven by the underlying adrenal histopathologic features. 
The 5 of 28 patients with biochemical cure, predicted by 
steroid profiling to have absent+partial biochemical success 
at 6 to 12 months postadrenalectomy, potentially comprise 
patients who develop long-term recurrent PA.30,31 A prospec-
tive validation study with long-term follow-up should address 
this possibility.
Perspectives
The histopathology of adrenals from patients who are bio-
chemically cured after adrenalectomy for unilateral PA is 
quantitatively different from the adrenals from patients with 
absent+partial biochemical success. The absence of a func-
tional adenoma at pathology or the presence of cortical hyper-
plasia may indicate patients in whom follow-up, including 
assessment of biochemical parameters, should be considered 
mandatory. Measurements of adrenal steroids in peripheral 
venous plasma are associated with adrenal histopathology 
and biochemical outcomes after surgery. This highlights the 
potential application of steroid profiling to guide the decision 
to perform surgery in patients who are being considered for 
adrenalectomy on the basis of a preoperative diagnosis of uni-
lateral PA.
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What Is New?
•	The absence of a functional solitary adenoma or the presence of cortical 
hyperplasia is associated with partial+absent biochemical success after 
surgery for unilateral primary aldosteronism.
•	Steroid profiling was associated with the presence or abence of solitary 
functional adenomas, cortical hyperplasia, and aldosterone-producing 
cell clusters.
•	Steroid profiling classifies the majority of patients according to complete 
or partial+absent biochemical success after unilateral adrenalectomy.
What Is Relevant?
•	Peripheral venous steroid profiling may be useful to select patients with 
a preoperative diagnosis of unilateral primary aldosteronism for surgery 
based on expectations of biochemical outcome.
Summary
Immunohistopathology may help determine which patients are 
likely to need ongoing follow-up for persistent primary aldosteron-
ism, and steroid profiling may be useful to guide the decision to 
perform surgery.
Novelty and Significance
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